- Home
- BRIA vs CTSO Comparison
BRIA vs CTSO Comparison
Compare BRIA & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- CTSO
- Stock Information
- Founded
- BRIA 2011
- CTSO 1997
- Country
- BRIA Singapore
- CTSO United States
- Employees
- BRIA N/A
- CTSO N/A
- Industry
- BRIA
- CTSO Medical/Dental Instruments
- Sector
- BRIA
- CTSO Health Care
- Exchange
- BRIA NYSE
- CTSO Nasdaq
- Market Cap
- BRIA 62.0M
- CTSO 52.6M
- IPO Year
- BRIA 2024
- CTSO N/A
- Fundamental
- Price
- BRIA $2.38
- CTSO $1.07
- Analyst Decision
- BRIA
- CTSO Buy
- Analyst Count
- BRIA 0
- CTSO 2
- Target Price
- BRIA N/A
- CTSO $5.50
- AVG Volume (30 Days)
- BRIA 2.8K
- CTSO 136.2K
- Earning Date
- BRIA 08-15-2025
- CTSO 08-12-2025
- Dividend Yield
- BRIA N/A
- CTSO N/A
- EPS Growth
- BRIA N/A
- CTSO N/A
- EPS
- BRIA 92.24
- CTSO N/A
- Revenue
- BRIA $59,695,825.00
- CTSO $35,332,238.00
- Revenue This Year
- BRIA N/A
- CTSO $18.34
- Revenue Next Year
- BRIA N/A
- CTSO $19.82
- P/E Ratio
- BRIA $0.03
- CTSO N/A
- Revenue Growth
- BRIA 8.03
- CTSO 15.37
- 52 Week Low
- BRIA $1.78
- CTSO $0.71
- 52 Week High
- BRIA $4.38
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- CTSO 52.96
- Support Level
- BRIA N/A
- CTSO $0.93
- Resistance Level
- BRIA N/A
- CTSO $1.16
- Average True Range (ATR)
- BRIA 0.00
- CTSO 0.11
- MACD
- BRIA 0.00
- CTSO -0.02
- Stochastic Oscillator
- BRIA 0.00
- CTSO 45.77
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.